Does Red Light Therapy Help Macular Degeneration?

For dry age-related macular degeneration, red light therapy has the most credible clinical evidence of any retinal condition we review, but with a crucial caveat: that evidence belongs to one clinic-administered device, not to at-home gadgets. The Valeda Light Delivery System has a phase 3 trial and, as of 2024, FDA authorization for dry AMD. We grade red light therapy for AMD Promising on that basis, while being clear that consumer devices are not proven for it and that there is no good evidence for wet AMD. This review explains the distinction.

It is an evidence summary, not medical advice. We sell no hardware and grade the evidence as we find it.

Quick verdict

For dry AMD specifically, we grade red light therapy Promising, driven by the Valeda system’s phase 3 trial and FDA authorization. That is genuine, device-specific clinical evidence, which makes AMD unusual in this field. The honest limits are that the evidence is for a supervised clinic device, not at-home panels or masks, and that wet AMD is a different disease where anti-VEGF injections remain the standard of care.

What is macular degeneration?

Age-related macular degeneration is a leading cause of vision loss in older adults, affecting the macula, the central part of the retina responsible for sharp, detailed vision. The common, slowly progressing form is dry AMD, marked by deposits called drusen and gradual thinning of retinal cells. A smaller share progresses to wet AMD, where abnormal blood vessels leak and threaten rapid central vision loss.

The retina is one of the most energy-demanding tissues in the body, packed with mitochondria, which is the rationale for studying photobiomodulation in retinal aging: the idea that red and near-infrared light can support struggling retinal cells.

What the evidence shows

The standout evidence is the LIGHTSITE III trial of the Valeda Light Delivery System, a multicenter sham-controlled study that reported improved best-corrected visual acuity in dry AMD (Boyer et al., 2024). A sham-controlled trial of an actual device is exactly the standard of evidence most light-therapy claims lack.

On the strength of that trial, the FDA authorized Valeda for dry AMD in late 2024, making it the first photobiomodulation device cleared for an eye disease (FDA, 2024).

The mechanism fits the broader ocular literature, in which red and near-infrared light is absorbed by retinal mitochondria to support cell function (Gaspari et al., 2024). The treatment uses several wavelengths delivered in a short, supervised session, repeated as a course over the year, which is part of why it sits in the clinic rather than the home.

The essential caveat is that this evidence is for one specific clinic system delivered as a supervised course. It does not transfer to at-home masks, glasses, or panels that emit similar wavelengths but have not been through equivalent trials.

At-home versus clinic for AMD

For AMD, the gap between clinic and home is at its widest. Valeda is administered in an eye-care practice as a course of sessions repeated periodically, and it is the option with both trial evidence and regulatory standing. At-home devices may use comparable wavelengths, but none has demonstrated an AMD benefit in its own trial, so for a serious, sight-threatening condition the clinic route is the evidence-based one.

If you are weighing options, our Valeda comparison sets the clinic system against at-home devices, and our eye-device buying guide scores the field. Anyone with AMD should make these decisions with a retinal specialist.

It is also worth being realistic about access and cost. Because Valeda is delivered as a repeated in-clinic course rather than a one-time purchase, the practical commitment is ongoing, and availability depends on finding a practice that offers it. That is a fair trade for the only option with a pivotal trial behind it, but it is a different proposition from buying a mask once, and it is part of the decision a specialist can help you weigh.

What it cannot do

Red light therapy is not a cure for AMD, and it does not reverse vision already lost. The evidence is for slowing or modestly improving function in dry AMD with a specific device, not for restoring sight. There is no good evidence it helps wet AMD, where anti-VEGF injections remain the established treatment, and using light therapy as a substitute for that care would be a serious mistake. AMD also still calls for the standard measures your doctor recommends, such as the AREDS2 supplement approach where appropriate.

Frequently asked questions

Does red light therapy work for macular degeneration?

For dry AMD, one clinic device has real evidence: the Valeda system improved visual acuity in a phase 3 sham-controlled trial (Boyer et al., 2024) and received FDA authorization. We grade it promising, but this applies to that supervised device, not at-home gadgets.

Is any red light device FDA approved for AMD?

Yes, one. The FDA authorized the clinic-based Valeda Light Delivery System for dry AMD in 2024, the first photobiomodulation device cleared for an eye disease (FDA, 2024). Consumer devices are not authorized for AMD.

Can an at-home device treat my AMD?

There is no trial showing at-home masks or panels help AMD. The evidence is for a clinic system, so for a sight-threatening condition the supervised route is the evidence-based one; see our Valeda comparison.

Does red light therapy help wet AMD?

There is no good evidence it does. Wet AMD is treated with anti-VEGF injections, the standard of care, and light therapy is not a substitute. Discuss any wet AMD with a retinal specialist promptly.

Will it restore vision I have already lost?

No. The evidence is for slowing or modestly improving function in dry AMD, not for reversing established vision loss. Treat it as possible support within specialist care, not a cure.

The bottom line

Macular degeneration is the one retinal condition where red light therapy has device-specific clinical backing: the Valeda clinic system has a phase 3 trial and FDA authorization for dry AMD, which earns a Promising grade. The evidence does not extend to at-home devices or to wet AMD, and it is not a cure. Manage AMD with a retinal specialist, and for the device landscape see our Valeda comparison and eye-device buying guide.

This review is an educational summary of published evidence. It is not medical advice and does not create a doctor-patient relationship. Always talk to a qualified eye-care professional before starting any light-based therapy.